Skip to main content

Advertisement

Table 2 Resistance rates of S. aureus isolates in nine European countries - children <18

From: Primary care treatment guidelines for skin infections in Europe: congruence with antimicrobial resistance found in commensal Staphylococcus aureusin the community

    Resistance rates (%) (95% confidence intervals)
Country Swabs Isolates ofS. aureus Azithromycin Clindamycin Erythromycin Oxacillin Penicillin Fucidic acid Mupirocin
Austria 111 23 (20.7%) 30.4** (21.4-39.4) 13.0 (6.4-19.6) 30.4** (21.4-39.4) 0 73.9 (65.3-82.5) 4.3 (0.3-8.3) 0
Belgium 101 30 (22.9%) 16.7 (9.4-24) 16.6 (9.3-23.9) 16.6 (9.3-23.9) 0 63.3 (53.9-72.7) 0 0
Croatia 562 152 (27.0%) 5.3 (0.9-9.7) 4.6 (0.5-8.7) 5.3 (0.9-9.7) 0.7 (0-2.3) 88.2** (81.9-94.5) 0 0
France 309 94 (30.4%) 11.7 (5.4-18.0) 8.5 (3.0-14.0) 10.6 (4.6-16.6) 1.1 (0-3.1) 79.8 (71.9-87.7) 2.1 (0-4.9) 0
Hungary 930 171 (18.4%) 16.4** (9.1-23.7) 16.4 (9.1-23.7) 16.4 (9.1-23.7) 0.6 (0-2.1) 86.0** (79.2-92.8) 0 0
NL 323 119 (36.8%) 5.9 (1.3-10.5) 3.4 (0-7) 4.2 (0.3-8.1) 0 73.1 (64.4-81.8) 0.5 (0-1.9) 0
Spain 427 146 (34.4%) 12.3 (5.9-18.7) 10.3 (4.3-16.3) 12.3 (5.9-18.7) 0.7 (0-2.3) 91.8* (86.4-97.2) 0 3.4 (0 -7.0)
Sweden 345 104 (30.1%) 2.9 (0-6.2) 2.9 (0-6.2) 2.9 (0-6.2) 0 73.1* (64.4-81.8) 2.0 (0-4.7) 0
UK    No children in study sample due to ethical considerations
  1. **Significant difference with adults under p < 0.05.
  2. *Significant difference with adults under p < 0.1.